Australia markets closed

Elevation Oncology, Inc. (ELEV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.5800+0.1000 (+2.87%)
At close: 04:00PM EDT
3.5800 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 195.60M
Enterprise value 122.36M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.58
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.08

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-7.25%
S&P500 52-week change 325.59%
52-week high 35.8900
52-week low 30.3630
50-day moving average 34.3639
200-day moving average 31.9537

Share statistics

Avg vol (3-month) 31M
Avg vol (10-day) 31.14M
Shares outstanding 554.64M
Implied shares outstanding 654.64M
Float 825.15M
% held by insiders 11.75%
% held by institutions 176.99%
Shares short (15 Apr 2024) 44.95M
Short ratio (15 Apr 2024) 45.76
Short % of float (15 Apr 2024) 411.32%
Short % of shares outstanding (15 Apr 2024) 410.18%
Shares short (prior month 15 Mar 2024) 44.63M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.94%
Return on equity (ttm)-71.82%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -38.53M
Net income avi to common (ttm)-39.35M
Diluted EPS (ttm)-0.8500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)104.05M
Total cash per share (mrq)1.9
Total debt (mrq)30.81M
Total debt/equity (mrq)40.63%
Current ratio (mrq)46.22
Book value per share (mrq)1.47

Cash flow statement

Operating cash flow (ttm)-48.92M
Levered free cash flow (ttm)-36.49M